Phase 2 N=12 H-22411: BOTOX® for Peyronie's Disease
Peyronie's Disease
Primary: Average Percent Change of Penile Curvature in Degrees — -21.73; 2.429 percent change — p=0.5154
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=147 The Safety and Effectiveness of AA4500 in Subjects With Peyronie's Disease
Peyronie's Disease
Primary: Change From Baseline in Penile Curvature — -29.7; -11.0 Percent change from baseline — p=0.001
Phase 3 N=417 Study of AA4500 in the Treatment of Peyronie's Disease
Peyronie's Disease
Primary: Percentage Change From Baseline in Penile Curvature — -37.6; -21.3 percentage of curvature change — p=0.0005
Phase 3 N=415 Study of AA4500 in the Treatment of Peyronie's Disease
Peyronie's Disease
Primary: Percentage Change From Baseline in Penile Curvature — -30.5; -15.2 percentage of curvature change — p=.0059
Phase 3 N=347 A Study of AA4500 in Men With Peyronie's Disease
Peyronie's Disease
Primary: Percentage Change From Baseline in Penile Curvature — -34.4 percentage of curvature change
N/A N=110 Efficacy of Penile Traction Therapy Using a Novel Device
Penile Diseases
Primary: Adverse Events at Baseline — 2; 2; 1; 7 percentage of participants
Phase 3 N=189 A Phase 3, Open-label Study of the Safety and Effectiveness of AA4500 Administered Twice Per Treatment Cycle for up to Four Treatment Cycles (2 x 4) in Men With Peyronie's Disease
Peyronie's Disease
Primary: Percentage Change From Baseline in Penile Curvature — -36.3 percentage of curvature change
Phase 2 N=5 Clostridium Histolyticum Collagenase Injection for Urethral Disease
Urethral Stricture
Primary: Number of Subjects With Complication After Treatment — 0 Participants
N/A N=1,459 Priapism in Boys and Men With Sickle Cell Disease - Demographics, Characteristics and Prevalence
Priapism · Anemia, Sickle Cell
Primary: Enumeration of the Prevalence of Priapism in Males With Sickle Cell Anemia and Sickle Beta Zero Thalassemia. — 18; 58; 160; 189 participants
N/A N=110 Penile Length Restoration in Men With Diabetes Mellitus, Type II
Diabetes Mellitus, Type 2 · Penile Diseases
Primary: Penile Length Change Between Baseline and Month 6 — 0; 0.5; 0.5; 0.8 Median change from baseline (cm)
Phase 1 N=59 Shockwave Therapy and Platelet Rich Plasma for the Treatment of Erectile Dysfunction
Erectile Dysfunction
Primary: Number of Participants With Treatment Emergent Serious Adverse Events (TE-SAEs) During the Study Period. — 0; 0 Participants
Phase 2 N=20 Pharmacokinetics of a Single Treatment Cycle of AA4500 0.58 mg in Men With Peyronie's Disease
Peyronie's Disease
Primary: AUX-I Cmax After Injection 1 — 12.6 ng/mL
N/A N=40 Evaluation of the Coloplast Titan® IPP for Maintaining Penile Length While Treating Erectile Dysfunction (ED)
Erectile Dysfunction
Primary: The Study's Primary Objective Will Assess the Change in Penile Length. — 1.14; 0.99; 1.04; 0.94 cm
N/A N=82 Penile Length Maintenance Post-Prostatectomy
Prostate Cancer · Penile Diseases
Primary: Change in Penile Length — 0.3; 1.6 centimeters
Phase 3 N=22 Evaluation of Xiaflex: Trial of Effectivenss iN Dupuytren's
Dupuytren's Disease
Primary: Health-related Quality of Life (HRQL) Using the Michigan Hand Outcomes Questionnaire (MHQ) — 78.1; 68.3 units on a scale — p=0.05
Phase 2 N=61 Safety and Efficacy of Autologous Platelet-Rich Plasma for Erectile Dysfunction.
Erectile Dysfunction
Primary: Number of Participants Achieving MCID in IIEF-EF. — 14; 15; 10; 13 Participants
Phase 3 N=308 AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Dupuytren's Contracture
Dupuytren's Contracture
Primary: Clinical Success (Reduction in Contracture to 5° or Less) of the Primary Joint After the Last Injection — 64; 6.8 Percentage of Joints — p=<0.001
N/A N=80 Radial Shockwave Therapy for Erectile Dysfunction
Erectile Dysfunction
Primary: Change IIEF-EF Score — 3.4; 4.2 units on a scale
Phase 3 N=66 Non-US Study of AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Advanced Dupuytren's Disease
Advanced Dupuytren's Disease
Primary: Reduction in Primary Joint Contracture to 5° or Less — 44.4; 4.8 Percentage of Joints — p=<.001
Phase 4 N=5 MRI Results in Dupuytren's Contracture Before and After Injection With Xiaflex
Dupuytren's Disease
Primary: The Measured Change in Volume of the Cord by MRI Before and After XIAFLEX Injection and Manual Manipulation. — 482 mm^3 — p=<0.0013
Phase 3 N=254 Treatment Of Dupuytren's Contracture With Collagenase Clostridium Histolyticum Injection (Xiapex)
Dupuytren's Contracture
Primary: Total Passive Extension Deficit (TPED) at Baseline for First Injection — 55.0 degrees
N/A N=98,832 Identification of Underlying Conditions in Men Prescribed a PDE5 Inhibitor
Erectile Dysfunction · Cardiovascular Diseases · Male Urogenital Diseases
Primary: Percentage of Participants With Underlying Condition Until Day -1 of the Index PDE5i Prescription — 70.23; 55.73 Percentage of participants — p=<0.001
N/A N=12 Erectile Rating During the Treatment of Rectal Cancers Localized
Rectal Cancer Stage I
Primary: Proportion of Patients With Erectile Dysfunction Induced by Medical and Surgical Treatment of Rectal Cancer — 0 Participants
N/A N=258 Dorsal Penile Nerve Block for Rigid Cystoscopy in Men
Pain
Primary: Visual Analog Scale (VAS) for Pain — 6; 4; 4 units on a scale
Phase 2 N=13 Sildenafil for Treatment of Priapism in Men With Sickle Cell Anemia
Sickle Cell Disease · Priapism
Primary: Greater Than or Equal to a 50% Reduction in Priapic Episodes — 3; 3 Number of participants — p=1
Phase 2 N=65 A Study of DS-1211b in Individuals With PseudoXanthoma Elasticum
Pseudoxanthoma Elasticum
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) in Participants Receiving DS-1211b — 8; 7; 6; 6 Participants
Phase 2 N=140 Repurposing Anti-TNF for Treating Dupuytren's Disease
Dupuytren's Disease
Primary: Early Disease: Nodule Hardness at 12 Months — 58.1; 61.2 Durometer Arbitrary Units (AU)
Phase 3 N=35 Collagenase in the Treatment of Dupuytrens Disease
Dupuytren's Disease
Primary: Primary Outcome Measure is Reduction of Flexion Contracture of the Primary Joint. — 91.3; 0 % Joints
Phase 3 N=201 Safety and Efficacy Study of AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Advanced Dupuytren's Disease
Advanced Dupuytren's Disease
Primary: Reduction in Contracture to 5° or Less — 52.7 percentage of joints
Phase 3 N=70 Botulinum Toxin for Erectile Dysfunction
Sexual Dysfunction · Erectile Dysfunction
Primary: Right (PSV R) and Left (PSV L) Cavernosal Artery Mean PSV Before Treatment — 34.52; 30.85; 34.33; 31.73 cm/sec